Granted Patent
B2
US 7,582,726 · App. 10/985,013 · Granted Sep 1, 2009
VEGF receptor antagonists
Assignee:
GHC Research Development Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention describes an approach to cancer therapy utilizing novel VEGF receptor antagonists. Specifically, the invention provides peptides and polynucleotides encoding VEGF receptor antagonists and methods of use thereof.
Claims (5)
1. A VEGF receptor antagonist consisting of KDR (Ig5-7).
2. A soluble VEGF receptor antagonist that consists essentially of SEQ ID NO:2.
3. A soluble VEGF receptor antagonist that consists essentially of SEQ ID NO:4.
4. The soluble VEGF receptor antagonist of claim 2 , consisting of SEQ ID NO:2.
5. The soluble VEGF receptor antagonist of claim 3 , consisting of SEQ ID NO:4.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 14, 2014
From: WAGNER, THOMAS E.
To: ORBIS HEALTH SOLUTIONS LLC
Reel/Frame 032665/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 31, 2009
From: GHC RESEARCH DEVELOPMENT CORPORATION AND GREENVILLE HOSPITAL SYSTEM
To: WAGNER, THOMAS E.
Reel/Frame 023720/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 3, 2007
From: GREENVILLE HOSPITAL SYSTEM
To: GHC RESEARCH DEVELOPMENT CORPORATION
Reel/Frame 019640/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 17, 2005
From: CHEN, WEN YUAN; PARK, JANG P.
To: GREENVILLE HOSPITAL SYSTEM
Reel/Frame 016572/0155 →
Continuity (2)
Provisional Application
6051829500
· Nov 10, 2003